Status:
COMPLETED
Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease
Lead Sponsor:
Wuhan General Hospital of Guangzhou Military Command
Conditions:
Left Ventriclar Mass
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
Cardiovascular disease is the most common cause of death in the world. Most of the attention in treating ischemic heart disease (IHD) is understandably directed toward treating coronary artery disease...
Eligibility Criteria
Inclusion
- They had to have normal glucose tolerance.
- They had to have either angiographically documented coronary artery disease or a previous history of myocardial infarction.
- They were required to have an office BP \< 130/80 mm Hg
- The presence of LVH on echocardiography (American Society of Echocardiography criteria LVM index \[LVMI\] \> 115 g/m2 for men and \> 95 g/m2 for women).
Exclusion
- They were currently prescribed metformin.
- They had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
- Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01879293
Start Date
July 1 2013
End Date
August 1 2015
Last Update
August 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan General Hospital
Wuhan, Hubei, China, 430070